Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Hematopoietic stem cell transplantation and cellular therapy.
HLA 89, 267-277 (2017)
Allogeneic stem cell transplantation is a form of immunotherapy that has increased the chances of survival for patients with relapsed leukemia and high risk leukemia in remission. The major obstacles are graft-vs-host disease (GVHD) involving vital organs and infections. A most efficacious prophylaxis of GVHD is by depleting of T cells from the graft. However, problems of T-depleted transplants are rejection, slow recovery of the immune system and high incidence of relapse of leukemia and myeloma. The major problem of allogeneic transplantation is the separation of a graft-vs-leukemia (GVL) effect from GVHD. This review will summarize the factors influencing GVHD, ways to exploit rapid advances in our knowledge of histocompatibility, chimerism and tolerance for fostering GVL over GVHD, and in particular the use of cellular therapies including donor lymphocyte infusions for disease control.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Allogeneic Hematologic Stem Cell Transplantation ; Leukemia ; Post-transplant Relapse; Versus-host-disease; Bone-marrow-transplantation; Donor Lymphocyte Infusion; Acute Myeloid-leukemia; Minor-histocompatibility-antigens; Chronic Myelogenous Leukemia; Necrosis-factor-alpha; Acute Graft; T-cells; Multiple-myeloma
ISSN (print) / ISBN
2059-2302
e-ISSN
2059-2310
Journal
HLA : immune response genetics
Quellenangaben
Volume: 89,
Issue: 5,
Pages: 267-277
Publisher
Wiley
Publishing Place
Oxford, UK
Reviewing status
Peer reviewed
Institute(s)
CCG Immunotherapy (KKG-KIT)